Loading…
Recently listed biotechnology company; specific pipeline and disease focus not confidently known.
Recently listed biotechnology company; specific pipeline and disease focus not confidently known.
Moat: none
Employees: 7
Size Damora Therapeutics (DMRA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.46B, the 2008th largest of 3,117 United States companies the cockpit tracks. Shares closed at $23.70 on 6 Nov 2026.
Performance Over six months the shares fell 1.9%, against -22.7% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Capital Return on invested capital runs 84.6 points below its cost of capital (12.5% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$96,000 | -$34,000 | -$181,000 | -$830,000 | -$490,000 |
| EBITDA | -$96.3M | -$36.5M | -$16.7M | -$35.6M | -$60.7M |
| Net income | -$263M | -$210M | -$21.4M | -$38.3M | -$61.6M |
| Free cash flow | -$44.5M | -$6.73M | -$18.6M | -$36.9M | -$43.1M |
| Capital expenditure | $0 | $0 | $0 | $0 | $196,000 |
| Total debt | $0 | $1.41M | $1.43M | $249,000 | $804,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DMRA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.3% | -3.6% | 3rd highest of 21 |
| 6-month return | -1.9% | -22.7% | 6th highest of 21 |
| Distance from 52-week high | -38.2% | -42.6% | 10th highest of 21 |
| ROIC minus cost of capital | -84.6 pp | -6.6 pp | 4th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 3.9× | 31.6% | +16.6% |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 2.2× | 14.9% | +11.1% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | 17.9× | n/a | n/a |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | 55.7× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.44B | -38% | +15% | -129% | 15.5× | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 2.3× | -8.5% | +4.6% |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 0.9× | -17.5% | +7.0% |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | 226.6× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 44.5× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | 3.3× | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 15.1× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 5.2× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 8.9× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | 4.9× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | 15.5× | n/a | n/a |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | 164.1× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | 13.6× | 49.9% | -13.2% |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 2.4× | -15.4% | +3.9% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 3.3× | 29.6% | +29.4% |